EPO and myelodysplastic syndrome: A prospective, randomized, phase 3 study compared the outcomes of patients treated with erythropoietin with or without granulocyte colony-stimulating factor plus supportive care vs. supportive care alone in 118 anemic patients with lower-risk MDS.